<?xml version='1.0' encoding='utf-8'?>
<document id="8417175"><sentence text="Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient."><entity charOffset="20-30" id="DDI-PubMed.8417175.s1.e0" text="zidovudine" /><entity charOffset="61-69" id="DDI-PubMed.8417175.s1.e1" text="oxazepam" /><pair ddi="false" e1="DDI-PubMed.8417175.s1.e0" e2="DDI-PubMed.8417175.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8417175.s1.e0" e2="DDI-PubMed.8417175.s1.e1" /></sentence><sentence text="This three-phase study was designed to determine if a pharmacokinetic drug-drug interaction exists between zidovudine and oxazepam"><entity charOffset="107-117" id="DDI-PubMed.8417175.s2.e0" text="zidovudine" /><entity charOffset="122-130" id="DDI-PubMed.8417175.s2.e1" text="oxazepam" /><pair ddi="false" e1="DDI-PubMed.8417175.s2.e0" e2="DDI-PubMed.8417175.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8417175.s2.e0" e2="DDI-PubMed.8417175.s2.e1" /></sentence><sentence text=" Six individuals infected with human immunodeficiency virus (HIV) and receiving zidovudine at 500 mg daily, with normal renal and hepatic function, were enrolled"><entity charOffset="80-90" id="DDI-PubMed.8417175.s3.e0" text="zidovudine" /></sentence><sentence text=" During phase I, zidovudine pharmacokinetics were studied after steady-state oral administration (100 mg every 4 h) and after a single dose (70 mg) of intravenous zidovudine"><entity charOffset="17-27" id="DDI-PubMed.8417175.s4.e0" text="zidovudine" /><entity charOffset="163-173" id="DDI-PubMed.8417175.s4.e1" text="zidovudine" /><pair ddi="false" e1="DDI-PubMed.8417175.s4.e0" e2="DDI-PubMed.8417175.s4.e0" /><pair ddi="false" e1="DDI-PubMed.8417175.s4.e0" e2="DDI-PubMed.8417175.s4.e1" /></sentence><sentence text=" Phase II consisted of a single oral dose (30 mg) of oxazepam followed by a 48-h blood sampling period"><entity charOffset="53-61" id="DDI-PubMed.8417175.s5.e0" text="oxazepam" /></sentence><sentence text=" Phase III began with 48 h of concomitant zidovudine, 100 mg orally every 4 h, and oxazepam, 15 mg orally every 8 h, followed by concomitant dosing of intravenous zidovudine and oral oxazepam"><entity charOffset="42-52" id="DDI-PubMed.8417175.s6.e0" text="zidovudine" /><entity charOffset="83-91" id="DDI-PubMed.8417175.s6.e1" text="oxazepam" /><entity charOffset="163-173" id="DDI-PubMed.8417175.s6.e2" text="zidovudine" /><entity charOffset="183-191" id="DDI-PubMed.8417175.s6.e3" text="oxazepam" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e0" e2="DDI-PubMed.8417175.s6.e0" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e0" e2="DDI-PubMed.8417175.s6.e1" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e0" e2="DDI-PubMed.8417175.s6.e2" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e0" e2="DDI-PubMed.8417175.s6.e3" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e1" e2="DDI-PubMed.8417175.s6.e1" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e1" e2="DDI-PubMed.8417175.s6.e2" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e1" e2="DDI-PubMed.8417175.s6.e3" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e2" e2="DDI-PubMed.8417175.s6.e2" /><pair ddi="false" e1="DDI-PubMed.8417175.s6.e2" e2="DDI-PubMed.8417175.s6.e3" /></sentence><sentence text=" Zidovudine concentrations were determined by radioimmunoassay"><entity charOffset="1-11" id="DDI-PubMed.8417175.s7.e0" text="Zidovudine" /></sentence><sentence text=" Oxazepam concentrations were determined with use of a fluorescence polarization immunoassay"><entity charOffset="1-9" id="DDI-PubMed.8417175.s8.e0" text="Oxazepam" /></sentence><sentence text=" The calculated bioavailability was 0" /><sentence text="61 for zidovudine alone and 0"><entity charOffset="7-17" id="DDI-PubMed.8417175.s10.e0" text="zidovudine" /></sentence><sentence text="75 when administered in combination with oxazepam (p = 0"><entity charOffset="41-49" id="DDI-PubMed.8417175.s11.e0" text="oxazepam" /></sentence><sentence text="16)" /><sentence text=" Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1"><entity charOffset="27-37" id="DDI-PubMed.8417175.s13.e0" text="zidovudine" /><entity charOffset="68-76" id="DDI-PubMed.8417175.s13.e1" text="oxazepam" /><pair ddi="false" e1="DDI-PubMed.8417175.s13.e0" e2="DDI-PubMed.8417175.s13.e0" /><pair ddi="false" e1="DDI-PubMed.8417175.s13.e0" e2="DDI-PubMed.8417175.s13.e1" /></sentence><sentence text="17 h versus 0" /><sentence text="99 h, respectively (p = 0" /><sentence text="25), and 1" /><sentence text="38 h versus 1" /><sentence text="15 h (p = 0" /><sentence text="38) for intravenous zidovudine during single and combination therapy, respectively"><entity charOffset="20-30" id="DDI-PubMed.8417175.s19.e0" text="zidovudine" /></sentence><sentence text=" Total body clearance of zidovudine was not significantly altered by oxazepam (93 L/h vs"><entity charOffset="25-35" id="DDI-PubMed.8417175.s20.e0" text="zidovudine" /><entity charOffset="69-77" id="DDI-PubMed.8417175.s20.e1" text="oxazepam" /><pair ddi="false" e1="DDI-PubMed.8417175.s20.e0" e2="DDI-PubMed.8417175.s20.e0" /><pair ddi="false" e1="DDI-PubMed.8417175.s20.e0" e2="DDI-PubMed.8417175.s20.e1" /></sentence><sentence text=" 109 L/h, p = 0" /><sentence text="16)" /><sentence text=" The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9"><entity charOffset="75-83" id="DDI-PubMed.8417175.s23.e0" text="oxazepam" /></sentence><sentence text="8 L/h, 65" /><sentence text="7 L, and 5" /><sentence text="1 h, respectively" /><sentence text="(ABSTRACT TRUNCATED AT 250 WORDS)" /></document>